Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of the Safety of AAV2/8-LSPhGAA in Late-onset Pompe Disease

Trial Profile

A Phase 1 Study of the Safety of AAV2/8-LSPhGAA in Late-onset Pompe Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs ACTUS 101 (Primary)
  • Indications Glycogen storage disease type II
  • Focus Adverse reactions
  • Sponsors Actus Therapeutics
  • Most Recent Events

    • 22 Jan 2019 According to the Actus Therapeutics media release, first patient has been dosed in this trial.
    • 22 Jan 2019 Status changed from not yet recruiting to recruiting, according to the Actus Therapeutics media release.
    • 21 May 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top